top of page

Maze Therapeutics, which had its IPO earlier this year, is using insights from genetics to develop small molecules - its most advanced program is for a genetic kidney disease

blonca9
7 days ago
1 min read

CEO Jason Coloma walks us through the science that is taking place at the company's South San Francisco headquarters, and descrbies the development programs. The lead program for APOL1-Mediated Kidney Disease is in phase 2, and a second for PKU and Chronic Kidney Disease will have important healthy volunteer proof of concept data this quarter.

Recent Posts

IO Biotech CEO Mai-Britt Zocca discusses the phase 3 pivotal trial result of the cancer vaccine Cylembio in first line advanced melanoma - and the company's strategy ahead

IO Biotech CEO Mai-Britt Zocca discusses the phase 3 pivotal trial result of the cancer vaccine Cylembio in first line advanced melanoma - and the company's strategy ahead

Checking in on the progress of CAR-T for autoimmune conditions with the CEO of Kyverna - the company's first (and first for the field) registration intended trial will read in the first half of 2026

Checking in on the progress of CAR-T for autoimmune conditions with the CEO of Kyverna - the company's first (and first for the field) registration intended trial will read in the first half of 2026

Bay Area based Nosis Bio is leveraging AI to get its gene silencers specifically to precise cell types - it recently announced a development candidate to tackle fibrosis

Bay Area based Nosis Bio is leveraging AI to get its gene silencers specifically to precise cell types - it recently announced a development candidate to tackle fibrosis

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page